 SAN RAFAEL, Calif., July 2, 2021 PRNewswire -- BioMarin Pharmaceutical Inc. NASDAQ: BMRN today announced three oral presentations and nine poster presentations related to valoctocogene roxaparvovec, an investigational gene therapy for the treatment of adults with severe hemophilia A, at the International Society on Thrombosis and Haemostasis ISTH 2021 Virtual Congress being held July 17-21, 2021. 